Regeneron, Lilly move toward subcutaneous mAb cocktails to treat COVID

Companies developing mAbs against COVID-19 are moving to subcutaneous injection to ameliorate deployment problems that have plagued their uptake. 

FDA has authorized REGEN-COV (casirivimab/imdevimab) from  Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bamlanivimab from  Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. (NASDAQ:ABCL) in the outpatient setting. But both are administered IV, creating logistical barriers that have limited their use. ...